Unnamed: 0,title,date,stock,sentiment
107670.0,"Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C.  and Los Angeles County.",2020-05-13 12:49:00-04:00,ATRS,negative
107671.0,"HC Wainwright & Co. Maintains Buy on Antares Pharma, Lowers Price Target to $4.5",2020-05-06 07:14:00-04:00,ATRS,negative
107672.0,70 Biggest Movers From Yesterday,2020-05-06 05:26:00-04:00,ATRS,neutral
107673.0,Antares Pharma shares are trading lower after the company reported Q1 earnings results.,2020-05-05 14:00:00-04:00,ATRS,neutral
107674.0,51 Stocks Moving In Tuesday's Mid-Day Session,2020-05-05 12:22:00-04:00,ATRS,neutral
107675.0,"The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout",2020-05-05 08:00:00-04:00,ATRS,positive
107676.0,Antares Withdraws FY20 Guidance,2020-05-05 07:20:00-04:00,ATRS,neutral
107677.0,"Antares Pharma Q1 EPS $(0.010) Up From $(0.030) YoY, Sales $33.100M Beat $30.780M Estimate",2020-05-05 07:19:00-04:00,ATRS,neutral
107678.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,ATRS,neutral
107679.0,Shares of several healthcare companies are trading higher amid optimism that coronavirus cases in Asia are potentially easing. Global slowing cases could raise hopes of a sooner return to spending and economic activity. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic.,2020-04-07 07:48:00-04:00,ATRS,positive
107680.0,Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several U.S. hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.,2020-04-06 11:47:00-04:00,ATRS,positive
107681.0,Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.,2020-04-01 09:20:00-04:00,ATRS,negative
107682.0,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",2020-03-27 10:58:00-04:00,ATRS,positive
107683.0,"The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test",2020-03-24 08:20:00-04:00,ATRS,negative
107684.0,Stocks That Hit 52-Week Lows On Monday,2020-03-23 10:34:00-04:00,ATRS,negative
107685.0,"The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company",2020-03-20 07:44:00-04:00,ATRS,negative
107686.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-19 10:49:00-04:00,ATRS,negative
107687.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,ATRS,positive
107688.0,Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 10:18:00-04:00,ATRS,negative
107689.0,"Raymond James Maintains Strong Buy on Antares Pharma, Raises Price Target to $6",2020-03-04 07:22:00-05:00,ATRS,positive
107690.0,40 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-03-03 08:10:00-05:00,ATRS,neutral
107691.0,"The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More",2020-03-03 07:51:00-05:00,ATRS,positive
107692.0,"The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off",2020-02-29 14:52:00-05:00,ATRS,neutral
107693.0,10 Medical Instruments & Supplies Stocks Moving In Monday's Session,2020-01-27 12:44:00-05:00,ATRS,neutral
107694.0,Antares Pharma shares are trading higher after the company issued FY19 sales guidance above estimates.,2020-01-27 08:47:00-05:00,ATRS,positive
107695.0,Antares Pharma Sees FY2020 Sales $135M-155M vs $149.16M Est,2020-01-27 07:08:00-05:00,ATRS,neutral
107696.0,Antares Pharma Sees FY2019 Sales $120M vs $118.26M Est,2020-01-27 07:08:00-05:00,ATRS,neutral
107697.0,15 Stocks Moving in Tuesday's Pre-Market Session,2020-01-07 07:48:00-05:00,ATRS,neutral
107698.0,65 Biggest Movers From Yesterday,2020-01-03 04:36:00-05:00,ATRS,neutral
107699.0,42 Stocks Moving In Thursday's Mid-Day Session,2020-01-02 12:13:00-05:00,ATRS,neutral
107700.0,Antares Pharma shares are trading lower. Not seeing any news to justify the price action.,2020-01-02 10:36:00-05:00,ATRS,neutral
107701.0,"The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug",2019-12-04 07:06:00-05:00,ATRS,negative
107702.0,"The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug",2019-11-26 08:06:00-05:00,ATRS,positive
107703.0,Stocks That Hit 52-Week Highs On Monday,2019-11-25 10:19:00-05:00,ATRS,neutral
107704.0,Stocks That Hit 52-Week Highs On Friday,2019-11-22 10:17:00-05:00,ATRS,neutral
107705.0,"The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate",2019-11-22 08:18:00-05:00,ATRS,positive
107706.0,"The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon",2019-11-21 07:22:00-05:00,ATRS,positive
107707.0,Stocks That Hit 52-Week Highs On Wednesday,2019-11-20 10:12:00-05:00,ATRS,neutral
107708.0,"The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data",2019-11-20 07:25:00-05:00,ATRS,positive
107709.0,Stocks That Hit 52-Week Highs On Tuesday,2019-11-19 10:21:00-05:00,ATRS,neutral
107710.0,"The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout",2019-11-19 07:56:00-05:00,ATRS,neutral
107711.0,Antares Pharma Enters Into Global Development Agreement With Idorsia Pharmaceuticals,2019-11-19 05:29:00-05:00,ATRS,positive
107712.0,Stocks That Hit 52-Week Highs On Monday,2019-11-18 11:01:00-05:00,ATRS,neutral
107713.0,Stocks That Hit 52-Week Highs On Friday,2019-11-15 10:14:00-05:00,ATRS,neutral
107714.0,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing",2019-11-14 08:07:00-05:00,ATRS,positive
107715.0,"The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher",2019-11-13 07:10:00-05:00,ATRS,neutral
107716.0,Antares Pharma shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.,2019-11-05 08:36:00-05:00,ATRS,positive
107717.0,"Antares Pharma Q3 EPS $0.01 Beats $(0.02) Estimate, Sales $34.306M Beat $26.89M Estimate",2019-11-05 08:35:00-05:00,ATRS,neutral
107718.0,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment",2019-11-05 06:53:00-05:00,ATRS,negative
107719.0,Antares Pharma Announces Receipt of Final Payment From Sale of Zomajet Needle-Free Delivery System,2019-10-31 09:20:00-04:00,ATRS,neutral
107720.0,Antares Pharma Has Been Awarded A $8.3M Supply Contract From The Department Of Veterans Affairs,2019-09-10 10:50:00-04:00,ATRS,positive
107721.0,"The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering",2019-08-06 07:22:00-04:00,ATRS,positive
107722.0,40 Healthcare Stocks Moving In Friday's After-Market Session,2019-07-29 04:25:00-04:00,ATRS,neutral
107723.0,30 Healthcare Stocks Moving In Thursday's After-Market Session,2019-07-26 04:36:00-04:00,ATRS,neutral
107724.0,"Antares Pharma Reports Amendment To Existing Loan, Security Deal With Hercules Capital To Raise Available Debt Capital By $25M For Term Loan Of Up To $50M",2019-06-27 07:18:00-04:00,ATRS,neutral
107725.0,"The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data",2019-05-02 08:16:00-04:00,ATRS,positive
107726.0,Antares Pharma Reaffirms FY2019 Sales Guidance of $95M-105M versus $99.47M Est.,2019-05-02 08:13:00-04:00,ATRS,neutral
107727.0,"Antares Pharma Q1 EPS $(0.03) Beats $(0.04) Estimate, Sales $23.286M Beat $18.18M Estimate",2019-05-02 08:11:00-04:00,ATRS,neutral
107728.0,Antares Pharma Announces Receipt Of Orphan Drug Designation For The Treatment Of Ectopic Pregnancy With Methotrexate,2019-03-28 07:30:00-04:00,ATRS,neutral
107729.0,Antares Pharma Receives Orphan Designation For methotrexate,2019-03-26 13:05:00-04:00,ATRS,neutral
107730.0,70 Biggest Movers From Friday,2019-03-11 05:26:00-04:00,ATRS,neutral
107731.0,"Raymond James Maintains Strong Buy on Antares Pharma, Raises Price Target to $5.65",2019-03-04 09:47:00-05:00,ATRS,positive
107732.0,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems",2019-02-28 08:24:00-05:00,ATRS,positive
107733.0,"Antares Pharma Q4 EPS $0.04 Up From $(0.02) YoY, Sales $18.8M Up From $14.04M YoY",2019-02-28 07:23:00-05:00,ATRS,neutral
107734.0,Antares Pharma Raises FY2018 Sales Guidance from $60.0M-65.0M to $62.50M-65.0M vs $62.53M Est,2019-01-07 07:15:00-05:00,ATRS,neutral
107735.0,Antares Pharma Reports XYOSTED Injection For Adult Men Diagnosed With Testosterone Deficiency Now Commercially Available,2018-11-29 07:07:00-05:00,ATRS,neutral
107736.0,"Antares Pharma, Inc. Q3 EPS $(0.01) Beats $(0.02) Estimate, Sales $17.868M Beat $15.05M Estimate",2018-11-06 07:27:00-05:00,ATRS,neutral
107737.0,45 Biggest Movers From Yesterday,2018-10-03 05:40:00-04:00,ATRS,neutral
107738.0,38 Stocks Moving In Tuesday's Mid-Day Session,2018-10-02 13:51:00-04:00,ATRS,neutral
107739.0,"Antares Pharma Shares Resume Trade, Up 4.8%",2018-10-01 07:32:00-04:00,ATRS,positive
107740.0,Antares Pharma Shares To Resume Trade At 7:30 a.m. EDT,2018-10-01 07:06:00-04:00,ATRS,positive
107741.0,Antares Receives FDA Approval of Xyosted Injection for Testosterone Replacement Therapy in Adult Males,2018-10-01 07:00:00-04:00,ATRS,positive
107742.0,"Antares Pharma Halted, News Pending",2018-10-01 06:56:00-04:00,ATRS,neutral
107743.0,"REMINDER: Anatares Pharma Has FDA PDUFA Date for XYOSTED Tomorrow, September 29th",2018-09-28 08:57:00-04:00,ATRS,neutral
107744.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-09-23 16:10:00-04:00,ATRS,neutral
107745.0,26 Stocks Moving In Tuesday's Pre-Market Session,2018-09-04 08:01:00-04:00,ATRS,neutral
107746.0,Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates,2018-08-31 15:06:00-04:00,ATRS,neutral
107747.0,"The Daily Biotech Pulse: Aveo Slips On Stock Offering, FDA Greenlights Generic EpiPen, Pfenex Exec Resigns",2018-08-17 08:15:00-04:00,ATRS,negative
107748.0,23 Stocks Moving In Friday's Pre-Market Session,2018-08-17 08:02:00-04:00,ATRS,neutral
107749.0,"Antares Pharma Shares Close Up 4.1%, Up Another 6.1% After Hours On News Its Partner, Teva, Received FDA Approval For Its Generic Epinephrine, For Which Antares Has the Exclusive License to Market In The U.S.",2018-08-16 17:05:00-04:00,ATRS,positive
107750.0,Antares Pharma Announces FDA Approval Of Generic EpiPen Utilizing VIBEX Auto Injector,2018-08-16 16:55:00-04:00,ATRS,positive
107751.0,"FDA Statement Confirms Approval of Teva's Generic Version of Mylan's Epipen; Mylan Shares -0.4%, Teva +6.2%; BZ NOTE: Antares Pharma Has Exclusive License To Market Teva's Epinephrine in the U.S.",2018-08-16 13:09:00-04:00,ATRS,positive
107752.0,"Antares Pharma Shares Spike To High Of $3.42, Now Up ~7.5% On The Day As It Is Partners With Teva On The Generic EpiPen",2018-08-16 12:57:00-04:00,ATRS,positive
107753.0,55 Biggest Movers From Yesterday,2018-08-14 04:50:00-04:00,ATRS,neutral
107754.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,ATRS,negative
107755.0,"Antares Pharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $14.162M Beat $13.25M Estimate",2018-08-07 07:14:00-04:00,ATRS,negative
107756.0,52 Biggest Movers From Yesterday,2018-08-07 05:19:00-04:00,ATRS,neutral
107757.0,44 Stocks Moving In Monday's Mid-Day Session,2018-08-06 12:39:00-04:00,ATRS,neutral
107758.0,Antares Pharma shares are up 8.9% premarket after the company announced an agreement with Pfizer to develop a drug rescue pen.,2018-08-06 09:00:00-04:00,ATRS,positive
107759.0,Benzinga Pro's 5 Stocks To Watch Today,2018-08-06 08:51:00-04:00,ATRS,neutral
107760.0,26 Stocks Moving In Monday's Pre-Market Session,2018-08-06 08:04:00-04:00,ATRS,neutral
107761.0,Antares Pharma Announces a Development Agreement with Pfizer for Drug Rescue Pen,2018-08-06 07:09:00-04:00,ATRS,positive
107762.0,28 Stocks Moving In Thursday's Pre-Market Session,2018-07-05 07:56:00-04:00,ATRS,neutral
107763.0,Antares Pharma Announces Receipt of Third Installment From Sale of ZOMAJET Needle-Free Delivery System  For $4.75M,2018-05-30 07:03:00-04:00,ATRS,neutral
107764.0,"Antares Pharma Q1 EPS $(0.04) Misses $(0.03) Estimate, Sales $12.7M Miss $13.3M Estimate",2018-05-08 07:18:00-04:00,ATRS,negative
107765.0,22 Stocks Moving In Thursday's Pre-Market Session,2018-04-05 08:12:00-04:00,ATRS,neutral
107766.0,"Antares Pharma Announces Complete Response Resubmission Accepted, PDUFA Date Set For September 29, 2018",2018-04-05 07:00:00-04:00,ATRS,positive
107767.0,"Antares Pharma Says It Doesn't Need To Conduct Any New Clinical Studies To Support A Re-Submission Of XYOSTED's New Drug Application, Anticipates Resubmission Will Include Re-Analysis Of Existing Data, Address Labeling And Post-Approval Risk Mitigation",2018-03-27 07:05:00-04:00,ATRS,positive
107768.0,Antares Pharma Announces It Will Not Attend The Cowen Healthcare Conference March 14th Due To Blizzard Conditions,2018-03-13 17:48:00-04:00,ATRS,neutral
107769.0,"Antares Pharma Reports Q4 EPS $(0.02) vs $(0.03) Est., Sales $14.04M vs $15.65M Est.",2018-03-13 07:14:00-04:00,ATRS,neutral
107770.0,"Earnings Scheduled For March 13, 2018",2018-03-13 05:20:00-04:00,ATRS,neutral
107771.0,46 Biggest Movers From Yesterday,2018-02-16 05:19:00-05:00,ATRS,neutral
107772.0,40 Stocks Moving In Thursday's Mid-Day Session,2018-02-15 12:11:00-05:00,ATRS,neutral
107773.0,22 Stocks Moving In Thursday's Pre-Market Session,2018-02-15 08:41:00-05:00,ATRS,neutral
107774.0,"Antares Pharma Announces FDA Approval of Partner AMAG's Product Makena Auto Injector, Was Announced By AMAG Wednesday Evening",2018-02-15 07:03:00-05:00,ATRS,positive
107775.0,AMAG Pharma Reports FDA Approval Of Makena For At-Risk Women Preterm Birth,2018-02-14 18:03:00-05:00,ATRS,positive
107776.0,REMINDER: AMAG Pharma and Antares Pharma Have FDA PDUFA Date Today for Makena Auto-Injector sNDA,2018-02-14 07:01:00-05:00,ATRS,neutral
107777.0,"The Week Ahead: Earnings, FDA Actions, And Industry Conferences To Watch",2018-02-12 14:06:00-05:00,ATRS,neutral
107778.0,Attention Biotech Investors: February PDUFA Catalysts Come Calling,2018-01-31 15:30:00-05:00,ATRS,neutral
107779.0,Mid-Afternoon Market Update: Shutterfly Surges On Earnings Beat; Forterra Shares Slide,2018-01-31 14:31:00-05:00,ATRS,positive
107780.0,Mid-Day Market Update: Cascadian Therapeutics Jumps Following Acquisition News; Bellicum Pharmaceuticals Shares Plunge,2018-01-31 12:07:00-05:00,ATRS,positive
107781.0,Mid-Morning Market Update: Markets Open Higher; Boeing Beats Q4 Estimates,2018-01-31 10:25:00-05:00,ATRS,neutral
107782.0,Antares Pharma Has a Meeting with the FDA on February 21 for XYOSTED,2018-01-16 07:09:00-05:00,ATRS,neutral
107783.0,Antares Pharma Offers Regulatory Update For XYOSTED: Written Request For Type A Meeting Submitted To FDA,2017-12-21 16:03:00-05:00,ATRS,neutral
107784.0,"Antares Pharma Reports Q3 EPS $(0.03) vs $(0.03) Est., Sales $15.1M vs $13.9M Est.",2017-11-07 07:22:00-05:00,ATRS,neutral
107785.0,31 Stocks Moving In Wednesday's Pre-Market Session,2017-10-25 08:08:00-04:00,ATRS,neutral
107786.0,Antares Pharma Shares Down 11.01% Premarket; Friday Co. Announced Receipt Of CRL From the FDA for XYOSTED,2017-10-23 08:59:00-04:00,ATRS,positive
107787.0,REMINDER: Antares Pharma Has PDUFA Date For VIBEX QuickShot Friday Oct. 20,2017-10-19 18:03:00-04:00,ATRS,neutral
107788.0,Vetr Urges Buy On Antares Post-Correction,2017-10-17 07:47:00-04:00,ATRS,neutral
107789.0,35 Biggest Movers From Yesterday,2017-10-17 04:52:00-04:00,ATRS,neutral
107790.0,30 Stocks Moving In Monday's Mid-Day Session,2017-10-16 12:32:00-04:00,ATRS,neutral
107791.0,"The Week Ahead: Earnings, Earnings, And More Earnings",2017-10-16 10:49:00-04:00,ATRS,neutral
107792.0,28 Stocks Moving In Monday's Pre-Market Session,2017-10-16 08:17:00-04:00,ATRS,neutral
107793.0,38 Biggest Movers From Friday,2017-10-16 04:39:00-04:00,ATRS,neutral
107794.0,Mid-Afternoon Market Update: Applied Optoelectronics Drops On Q3 Warning; PhaseRx Shares Surge,2017-10-13 14:31:00-04:00,ATRS,negative
107795.0,35 Stocks Moving In Friday's Mid-Day Session,2017-10-13 12:31:00-04:00,ATRS,neutral
107796.0,Mid-Day Market Update: Crude Oil Up Over 1%; Tandem Diabetes Care Shares Plunge,2017-10-13 12:02:00-04:00,ATRS,positive
107797.0,Mid-Morning Market Update: Markets Open Higher; Bank of America Profit Beats Expectations,2017-10-13 10:14:00-04:00,ATRS,positive
107798.0,28 Stocks Moving In Friday's Pre-Market Session,2017-10-13 08:03:00-04:00,ATRS,neutral
107799.0,12 Stocks Moving In Thursday's After-Hours Session,2017-10-12 17:14:00-04:00,ATRS,neutral
107801.0,Antares Pharma Reports Receipt Of FDA Letter Including Notice Of Deficiencies In XYOSTED NDA,2017-10-12 17:01:00-04:00,ATRS,neutral
107802.0,Seeing Notable Block Trade In Antares Pharma; 1.4M Shares At $3.85 Above The Ask,2017-10-12 13:35:00-04:00,ATRS,negative
107803.0,"Attention Biotech Investors, Here's Your PDUFA Primer For October",2017-09-28 10:51:00-04:00,ATRS,neutral
107804.0,"Antares Pharma Reports Q2 EPS $(0.02) vs $(0.03) Est., Sales $13.4M vs $12.5M Est.",2017-08-08 07:12:00-04:00,ATRS,neutral
107805.0,Antares Pharma Given 5-Star Upgrade By Vetr,2017-07-26 09:34:00-04:00,ATRS,neutral
107806.0,15 Biggest Mid-Day Gainers For Friday,2017-06-23 12:26:00-04:00,ATRS,neutral
107807.0,"Benzinga's Top Upgrades, Downgrades For June 23, 2017",2017-06-23 09:23:00-04:00,ATRS,positive
107808.0,"CORRECTION: H.C. Wainwright Initiates Coverage On Antares Pharma with Buy Rating, Announces $5.00 Price Target",2017-06-23 08:09:00-04:00,ATRS,neutral
107809.0,"H.C. Wainwright Initiates Coverage On Antares Pharma with Buy Rating, Announces $5.00 Price Target",2017-06-23 07:12:00-04:00,ATRS,neutral
107810.0,15 Biggest Mid-Day Gainers For Tuesday,2017-06-13 12:39:00-04:00,ATRS,neutral
107811.0,Antares Pharma Reports $35M in Debt Financing from Hercules Capital,2017-06-07 07:06:00-04:00,ATRS,negative
107812.0,S-3 from Antares Pharma Shows Registration for $200M Mixed Securities Shelf Offering,2017-05-09 17:06:00-04:00,ATRS,positive
107813.0,"Antares Pharma Q1 EPS $(0.03) vs $(0.03) Est, Sales $12.0M vs $12.3M Est",2017-05-09 07:22:00-04:00,ATRS,neutral
107814.0,"Raymond James Initiates Coverage On Antares Pharma With Strong Buy, Announces $4.30 Price Target",2017-04-21 08:59:00-04:00,ATRS,positive
107815.0,"Antares Pharma Q4 EPS $(0.03) vs $(0.04) Est, Sales $14.2M vs $11.3M Est",2017-03-14 07:03:00-04:00,ATRS,neutral
107816.0,Antares Pharma Reports FDA Acceptance of New Drug Application for Quickshot Testosterone,2017-02-27 07:01:00-05:00,ATRS,positive
107817.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-01-31 08:22:00-05:00,ATRS,neutral
107818.0,Antares Pharma Announces Submission of New Drug Application for Quickshot Testosterone,2016-12-21 08:02:00-05:00,ATRS,neutral
107819.0,Antares Pharma Announces Completion of Teva's Decentralized Procedure for Teriparatide Injection in Europe,2016-12-19 07:08:00-05:00,ATRS,neutral
107820.0,"ANTARES PHARMA, INC.: Powell Fred M (Senior Vice President & CFO) Buys 100,000 @ Avg Price: $2.02 (Form4",2016-12-12 16:31:00-05:00,ATRS,neutral
107821.0,10 Stocks With Three-Day Increasing Volume,2016-11-29 06:30:00-05:00,ATRS,neutral
107822.0,Antares Pharma Names Fred Powell CFO,2016-10-31 09:05:00-04:00,ATRS,neutral
107823.0,20 Stocks That Rallied Three Days On No News,2016-10-28 05:58:00-04:00,ATRS,negative
107824.0,15 Stocks With Three-Day Increasing Volume,2016-09-16 06:58:00-04:00,ATRS,neutral
107825.0,10 Biggest Mid-Day Losers For Monday,2016-08-29 13:11:00-04:00,ATRS,negative
107826.0,Have You Heard About This Generic EpiPen Maker?,2016-08-24 09:01:00-04:00,ATRS,neutral
107827.0,"FBN 'Closing Bell' Anchor Liz Claman Tweets 'OUTRAGE: for 1yr now Robyn O'Brien @foodawakenings has been screaming about price hikes of #epipen WAS $57, NOW $700 for 2? 3pET Justified?'",2016-08-23 13:48:00-04:00,ATRS,negative
107828.0,Antares Pharma Shares Up 16% as Co. is Supplier to Teva's Generic Version of EpiPen; BZ NOTE: Mylan Shares Have Been Under Pressure Last Two Sessions Following Major Price Increase to EpiPen,2016-08-23 10:30:00-04:00,ATRS,positive
107829.0,Antares Pharma Announces Resignation of CFO James E. Fickenscher,2016-08-11 07:08:00-04:00,ATRS,negative
107830.0,"Antares Pharma Reports Q2 EPS $(0.04) vs. Est. $(0.04), Rev. $12.2M vs. Est. $11M",2016-08-09 07:24:00-04:00,ATRS,neutral
107831.0,Teva and Antares Pharma Launch of Generic Imitrex in the United States,2016-06-27 08:34:00-04:00,ATRS,positive
107832.0,"Antares Pharma Reports Settlement of Patent Litigation for Key Alliance Business Product, Settlement Between AstraZeneca and Teva Allows Teva to Commercialize Its Generic Version of BYETTA on October 15, 2017",2016-06-23 10:55:00-04:00,ATRS,negative
107833.0,Antares Pharma Announces Last Patient Has Finished Treatment in Phase 3 Study,2016-06-01 07:07:00-04:00,ATRS,neutral
107834.0,"Antares Pharma Reports Q1 EPS $(0.05) vs. Est. $(0.03), Rev. $12.3M vs. Est. $11M",2016-05-09 07:20:00-04:00,ATRS,neutral
107835.0,Antares Pharma Additional Dosage Strengths of Otrexup Injection Approved by FDA,2016-03-29 07:05:00-04:00,ATRS,positive
107836.0,Antares Pharma Reports Added Dosage Strengths of Otrexup Injection Approved by FDA,2016-03-29 07:03:00-04:00,ATRS,positive
107837.0,Peter Graham Buys 20K Shares of Antares Pharma @$0.77/Share -Form 4,2016-03-23 08:57:00-04:00,ATRS,positive
107838.0,Robert Roche Buys 50K Shares of Antares Pharma @$0.72/Share -Form 4,2016-03-22 09:01:00-04:00,ATRS,positive
107839.0,Antares Pharma Reports Completion Of 52 Week Phase 3 QuickShot Study in Testosterone Deficient Men,2016-03-16 07:04:00-04:00,ATRS,neutral
107840.0,"Jefferies Maintains Buy on Antares Pharma, Lowers PT to $3.00",2016-03-09 08:18:00-05:00,ATRS,negative
107841.0,"Jefferies Maintains Buy on Antares Pharma, Lowers PT to $3.00",2016-03-09 08:17:00-05:00,ATRS,negative
107842.0,"Antares Pharma Reports Q4 EPS $(0.04) vs. Est. $(0.03), Rev. $11.8M vs. Est. $12.53M",2016-03-08 07:03:00-05:00,ATRS,neutral
107843.0,Mid-Afternoon Market Update: Crude Oil Climbs 6%; Sprint Shares Gain Following Strong Q3 Earnings,2016-01-26 14:40:00-05:00,ATRS,positive
107844.0,Antares Pharma Surges Following Announcement Of CEO Change,2016-01-26 12:21:00-05:00,ATRS,neutral
107845.0,"Antares Pharma Names Robert Apple CEO, To Succeed Eamonn Hobbs; Mr. Apple Comments On Upcoming Catalysts",2016-01-26 08:08:00-05:00,ATRS,positive
107846.0,Antares Pharma +19% Premarket @$1.50 Following Announcement of FDA Approval of Sumatriptan Injection,2015-12-14 09:12:00-05:00,ATRS,positive
107847.0,Antares Pharma Reports FDA Approval of Sumatriptan Injections,2015-12-14 09:01:00-05:00,ATRS,positive
107848.0,Antares Pharma Announces Update to Quickshot Testosterone Clinical Program,2015-10-30 07:11:00-04:00,ATRS,neutral
107849.0,Stocks Hitting 52-Week Lows,2015-10-20 11:57:00-04:00,ATRS,negative
107850.0,Antares Pharma Reports Publication of QuickShot Testosterone Data in Prestigious Health Journal,2015-09-28 07:01:00-04:00,ATRS,neutral
107851.0,"Antares Pharma Q2 EPS -$0.01 vs -$0.03 est, Revenue $14.4M vs $10.9M est",2015-08-10 07:04:00-04:00,ATRS,neutral
107852.0,Antares Pharma Announces First Patients Enrolled In QuickShot Testosterone Supplemental Safety Study,2015-08-04 07:00:00-04:00,ATRS,positive
107853.0,Antares Pharma Spikes to High on Volume,2015-07-21 12:22:00-04:00,ATRS,neutral
107854.0,"Antares Pharma Names Peter Graham as Senior VP, General Counsel, Human Resources, Chief Compliance Officer, Corporate Secretary",2015-07-14 08:00:00-04:00,ATRS,neutral
107855.0,"Antares Pharma Names Peter Graham as Senior VP, General Counsel, Human Resources, Chief Compliance Officer, Corporate Secretary",2015-07-14 07:07:00-04:00,ATRS,neutral
107856.0,Antares Pharma Updates QuickShot Testosterone Program,2015-06-01 07:00:00-04:00,ATRS,neutral
107857.0,"Jefferies Initiates Coverage on Antares Pharma at Buy, Announces $5.00 PT",2015-05-28 06:16:00-04:00,ATRS,neutral
107858.0,Benzinga's Top Initiations,2015-05-18 09:22:00-04:00,ATRS,positive
107859.0,Piper Jaffray Initiates Antares Pharma With Overweight,2015-05-18 08:56:00-04:00,ATRS,negative
107860.0,"Piper Jaffray Initiates Coverage on Antares Pharma at Overweight, Announces $3.50 PT",2015-05-18 06:16:00-04:00,ATRS,negative
107861.0,"Antares Report Q1 EPS $(0.05) vs. Est. $(0.04), Rev. $8.3M vs. Est. $9.32M",2015-05-11 07:01:00-04:00,ATRS,neutral
107862.0,Antares Pharma Reports Proposed Common Stock Offering,2015-05-05 16:08:00-04:00,ATRS,neutral
107863.0,Antares Pharma Announces Regained US Marketing Rights to OTREXUP for Psoriasis,2015-04-27 07:03:00-04:00,ATRS,neutral
107864.0,Antares Pharma And Medac Pharma Settle Suit,2015-04-16 07:06:00-04:00,ATRS,neutral
107865.0,Antares IR Says No News Connected to Unusual Call Activity,2015-04-09 15:31:00-04:00,ATRS,negative
107866.0,Option Alert: Antares Pharma Aug $5 Call; 1101 Contract Trade at Ask @$0.25: Now $2.87,2015-04-09 14:50:00-04:00,ATRS,positive
107867.0,US Stock Futures Slide Ahead Of Economic Data,2015-03-31 07:40:00-04:00,ATRS,neutral
107868.0,Antares Pharma Announces FDA Approval of TEV-TROPIN 10 mg Needle-Free Injector,2015-03-31 07:03:00-04:00,ATRS,positive
107869.0,Antares Pharma Provides Regulatory Update on Sumatriptan Injection USP,2015-01-26 07:01:00-05:00,ATRS,neutral
107870.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4,2015-01-13 11:34:00-05:00,ATRS,neutral
107871.0,Morning Market Losers,2015-01-13 10:01:00-05:00,ATRS,negative
107872.0,Tuesday Morning Movers: ChannelAdvisor Plummets,2015-01-13 09:29:00-05:00,ATRS,neutral
107873.0,Mid-Day Market Update: ON Semiconductor Surges On $1 Billion Buyback Plan; POZEN Shares Slip,2014-12-01 13:43:00-05:00,ATRS,positive
107874.0,"Antares Pharma Appoints James Fickenscher As CFO, SVP",2014-11-18 07:01:00-05:00,ATRS,neutral
107875.0,"Antares Pharma, Inc. Reports Q3 EPS of $(0.05) vs $(0.06) Est; Revenue of $6.57M vs $7.50M Est",2014-11-06 07:13:00-05:00,ATRS,neutral
107876.0,Antares Pharma Announces Last Patient Enrolled In Phase 3 QuickShot Study ,2014-11-03 07:01:00-05:00,ATRS,neutral
107877.0,"JMP Securities Initiates Coverage on Antares Pharma, Inc. at Outperform, Announces $4.00 PT",2014-10-22 05:29:00-04:00,ATRS,positive
107878.0,"Antares Pharma, Inc. Reports Q2 EPS of $(0.07), Inline; Revenue of $6.33M vs $6.43M Est",2014-08-07 07:27:00-04:00,ATRS,neutral
107879.0,Antares Announces First Patient Dosed in Phase 3 Study,2014-07-22 07:00:00-04:00,ATRS,neutral
107880.0,"Antares Pharma Announces Paul Wotton Has Resigned, Eamonn Hobbs Named as Pres, CEO",2014-06-24 09:01:00-04:00,ATRS,negative
107881.0,Antares Pharma Files $200M Mixed Securities Shelf,2014-05-16 17:08:00-04:00,ATRS,positive
107882.0,"Antares Pharma, Inc. Reports Q1 EPS of $(0.07) vs $(0.05) Est; Revenue of $5.20M vs $6.17M Est",2014-05-09 07:01:00-04:00,ATRS,neutral
107883.0,Antares Pharma Announces Additional Patent Coverage for OTREXUP,2014-04-16 07:21:00-04:00,ATRS,neutral
107884.0,Stocks Hitting 52-Week Lows,2014-04-11 10:17:00-04:00,ATRS,negative
107885.0,"Earnings Scheduled For March 13, 2014",2014-03-13 04:51:00-04:00,ATRS,neutral
107886.0,Antares Pharma Receives Second Milestone Payment from LEO Pharma in OTREXUP Collaboration ,2014-03-12 07:08:00-04:00,ATRS,neutral
107887.0,"Medac Files Lawsuit Against Antares Pharma, Leo Pharma for Patent Infringement",2014-03-11 10:18:00-04:00,ATRS,negative
107888.0,Antares Pharma Announces LEO Pharma's Launch of OTREXUP Injection to Dermatologists for Adults with Psoriasis ,2014-03-10 07:10:00-04:00,ATRS,neutral
107889.0,"Antares Pharma Announces Availability of OTREXUP Injection for Subcutaneous Use to Treat Rheumatoid Arthritis (RA) and Psoriasis in Adults, and Polyarticular Idiopathic Arthritis in Children ",2014-01-15 07:09:00-05:00,ATRS,positive
107890.0,Antares Pharma Awarded Additional U.S. Patent Protection for OTREXUP™ ,2013-11-26 07:05:00-05:00,ATRS,positive
107891.0,"Antares Pharma Reports Deal with Leo Pharma for Otrexup in Dermatology, Could Receive Up to $20M in Milestone Payments, Upfront Payment $5M",2013-11-14 09:08:00-05:00,ATRS,neutral
107892.0,"Antares Pharma, Inc. Reports Q3 EPS of $(0.05) vs $(0.04) Est; Revenue of $5.51M vs $5.86M Est",2013-11-06 07:03:00-05:00,ATRS,neutral
107893.0,Antares Pharma Announces Issuance of Patent for VIBEX Device Platform ,2013-10-25 07:03:00-04:00,ATRS,neutral
107894.0,Mid-Afternoon Market Update: Market Holds Awaiting Public Address From Congressional Leaders,2013-10-14 15:50:00-04:00,ATRS,neutral
107895.0,Mid-Day Market Update: US Stocks Pare Losses; Expedia Shares Drop Following Downgrade,2013-10-14 13:20:00-04:00,ATRS,negative
107896.0,Mid-Morning Market Update: Markets Open Lower; Facebook Acquires Onavo,2013-10-14 10:53:00-04:00,ATRS,negative
107898.0,Antares Pharma Says FDA Approves OTREXUP Injection for Adults with RA,2013-10-14 09:25:00-04:00,ATRS,positive
107899.0,Antares Shares Rise 13% on FDA Approval of Otrexup,2013-10-14 09:19:00-04:00,ATRS,positive
107900.0,"Jefferies Maintains Buy on Antares Pharma, Inc., Raises PT to $6.00",2013-10-08 07:47:00-04:00,ATRS,neutral
107901.0,"Market Wrap For Tuesday, October 1: Government Down, Markets Up",2013-10-01 16:36:00-04:00,ATRS,neutral
107902.0,Mid-Afternoon Market Update: Markets Remain Up As Government Shutdown Continues,2013-10-01 15:17:00-04:00,ATRS,neutral
107903.0,"Antares Pharma, Inc. Reports Q2 EPS of $(0.04) vs $(0.03) Est; Revenue of $5.80M vs $5.82M Est",2013-08-07 07:06:00-04:00,ATRS,neutral
107904.0,Antares Pharma Announces Issuance of New US Patent for Otrexup,2013-06-27 09:17:00-04:00,ATRS,neutral
107905.0,ViroPharma and Other Biotech Stocks Recommended by Oppenheimer (VPHM),2013-06-24 15:16:00-04:00,ATRS,positive
107906.0,UPDATE: Oppenheimer Assumes Antares Pharma at Outperform on Multiple Positive Factors,2013-06-21 08:42:00-04:00,ATRS,positive
107907.0,"Oppenheimer Reinstates Outperform on Antares Pharma, Inc., Announces $6.00 PT",2013-06-20 16:17:00-04:00,ATRS,neutral
107908.0,"Antares Pharma, Inc. Reports Q1 EPS of $(0.03), Inline; Revenue of $4.50M vs $5.12M Est",2013-05-08 07:06:00-04:00,ATRS,neutral
107909.0,Antares Pharma Announces the Issuance of a New Patent on VIBEX Device Platform ,2013-04-16 08:33:00-04:00,ATRS,neutral
107910.0,Antares Pharma Announces Notice of Allowance for New Patent on VIBEX™ QuickShot Device,2013-04-05 07:30:00-04:00,ATRS,neutral
107911.0,UPDATE: Jefferies Reiterates $5 PT and Buy Rating on Antares Pharma on In-Line 4Q Results,2013-03-14 14:39:00-04:00,ATRS,negative
107912.0,"Antares Pharma, Inc. Reports Q4 EPS of $(0.04) vs $(0.03) Est; Revenue of $5.50M vs $5.36M Est",2013-03-13 07:08:00-04:00,ATRS,neutral
107913.0,"Earnings Scheduled For March 13, 2013",2013-03-13 04:21:00-04:00,ATRS,neutral
107914.0,Antares Pharma Announce FDA Acceptance of NDA for OTREXUP,2013-02-27 07:34:00-05:00,ATRS,positive
107915.0,"UPDATE: Jefferies & Company Initiates Coverage on Antares Pharma with Buy Rating, $5 PT",2012-12-19 11:33:00-05:00,ATRS,neutral
107916.0,Benzinga's Top Initiations,2012-12-19 07:36:00-05:00,ATRS,positive
107917.0,"Jefferies Initiates Coverage on Antares Pharma, Inc. at Buy, Announces $5.00 PT",2012-12-19 06:19:00-05:00,ATRS,neutral
107918.0,"Guggenheim Securities Initiates Coverage on Antares Pharma at Buy, Announces PT of $6",2012-11-26 09:30:00-05:00,ATRS,positive
107919.0,Morning Market Losers,2012-10-03 09:53:00-04:00,ATRS,negative
107920.0,Antares Pharma Announces Pricing of 12M Share Offering at $4.00 per Share,2012-10-03 08:47:00-04:00,ATRS,positive
107921.0,Antares Pharma Announces Proposed Public Offering of Common Stock,2012-10-02 16:01:00-04:00,ATRS,neutral
107922.0,Antares Pharma Announces Successful Results from VIBEX MTX Trial,2012-09-25 07:09:00-04:00,ATRS,positive
107923.0,"Oppenheimer Maintains Antares Pharma at Outperform, Raises PT from $4 to $5",2012-08-08 13:32:00-04:00,ATRS,neutral
107924.0,Spokesperson for Antares Pharma Says There is No News to Account for Unusual Put Activity,2012-07-10 15:45:00-04:00,ATRS,negative
107925.0,"Option Alert: Antares Pharma Put Volume at 1,054% of Average; Currently $4.81",2012-07-10 15:34:00-04:00,ATRS,positive
107926.0,Antares Pharma Announces Positive Results from VIBEX MTX Usability Study   ,2012-06-26 07:01:00-04:00,ATRS,positive
107927.0,Antares Pharma Announces Move to the NASDAQ Stock Market   ,2012-06-06 07:01:00-04:00,ATRS,neutral
